Abstract: A nutritional supplement containing fish oil and selenium has been identified that potentiates radiotherapy of tumors in a synergistic fashion. Cotherapy with such a supplement and radiotherapy results in substantially improved reductions in tumor volume of animal models relative to radiotherapy alone, and reduces common side effects such as weight loss, inflammation, and damage to the gastrointestinal tract. Such cotherapy was also found to reduce the incidence of metastasis from the primary implantation site, and to modulate expression of genes associated with apoptosis in tumor cells. A formulation for such a supplement that is both well tolerated and palatable is also provided.

Abstract: A nutritional supplement that includes fish oil and selenium has been found to provide a variety of activities beneficial in treating cancer and associated conditions. Such a supplement provides synergistic effects in reducing cancer cell proliferation when used in combination with chemotherapeutic drugs, and can reduce proliferation in drug-resistant cancer cells when used in combination with chemotherapeutic drugs to which the cells are resistant. Effects in reducing angiogenesis, reducing metastasis, reducing the number of circulating cancer cells, and modifying AXL signaling were also found. In addition, use of such a supplement was found to reduce wasting associated with cachexia and reduce circulating cytokines associated with inflammation. Overall effects were found to extend survival in clinical studies.

Abstract: Provided is a hybrid nanoparticle, including an aggregate assembled from a plurality of polymeric molecules, and a plurality of boron-doped graphene quantum dots localized in the aggregate. The polymeric molecule is preferably a pH-responsive dendrimer; the polymeric molecule and the boron-doped graphene quantum dot may be separately associated with different drugs; and hybrid nanoparticle may further include a targeting molecule, such as a rabies virus glycoprotein. Also provided is a method of controlling disassembly of a hybrid nanoparticle, including applying a high-frequency magnetic field to the hybrid nanoparticle to induce disassembly thereof. Also provided is an application of the hybrid nanoparticle for preparing a tumor-penetrating drug carrier.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one pharmaceutically acceptable salt of giycopyrrolate; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: Provided are a conjugate including a core and sialic acids or derivatives thereof bound to the surface of the core, and use thereof. The conjugate provided in the present invention binds with hemagglutinin on the surface of influenza virus to inhibit the course of infection of influenza virus, thereby preventing or treating infection of influenza virus and also preventing or treating infection of influenza virus resistant to antiviral agents. Accordingly, the conjugate may be widely used in the development of prophylactic or therapeutic agents for influenza virus infection.

Abstract: Vitamin E compositions, methods of making such compositions and therapeutic uses of vitamin E compositions are disclosed. Compositions of matter comprising a tocotrienol making up at least 15 dry basis weight percent of the composition of matter and a constituent selected from a triglyceride and a triglyceride ester, wherein upon mixing of the composition of matter with water the tocotrienol based composition is substantially emulsified; and wherein upon mixing of the composition of matter with water a resulting emulsion has an intensity-weighed mean droplet size of less than 700 nm are also disclosed.

Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.

Abstract: Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: A nicotine lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. In some cases, a nicotine lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in a nicotine lozenge provided herein can include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.

Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

Abstract: Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Abstract: The present invention relates to compositions comprising terpenes and hollow glucan particles or cell wall particles and methods for preparing such compositions. The compositions increase terpene stability and activity and provide a suitable carrier for the terpenes. The invention also relates to methods of using such compositions in the medical, veterinary and agricultural fields.

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: The present invention relates to a cosmetic composition comprising: a) at least one UV filter; b) at least one composite particle in spherical form, having a mean size of between 0.1 and 30 ?m comprising at least one particulate UV-screening agent and a core constituted of at least one inorganic material and/or of at least one organic material; c) at least one anti-oxidation active ingredient chosen from I) a compound according to formula (I) wherein each X independently represents —OPO3Y, wherein Y is selected from hydrogen, Li, Na and K; II) a dimer peptide according to formula (II); III) a tocopherol or its derivatives; and IV) a mixture thereof.

Abstract: A method of quenching excited state energy from a photodegradable pigment that has been excited by absorption of light having a wavelength in the wavelength range of 290-800 nm, comprising reacting a pigment with a conjugated fused tricyclic compound having electron withdrawing groups of Formula (II) or a salt thereof: wherein: A is selected from the group consisting of O, S, C?O, C?S, B1, B2, D1 and D2 are each independently selected from the group consisting of F, Cl, Br, I, CF3, CC13, NR33+, NO2, CN, C(?O)R4, C(?O)OR?, SO2R5, aryl, and —C?CHR6; each m independently is 0, 1, 2, 3, or 4; a is 0 or 1; each R? is independently selected from the group consisting of LI, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl; R2 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl; each R3 is independently selected from the group consisting of H and C1-C6 alkyl; each R4 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl,

Abstract: A skin care fabric for medical, pharmaceutical or cosmetic use includes at least 80% by weight of microfibers that are a mixture of polyamide and polyester and have a diameter of less than 50 microns. Each microfiber is split to produce fine fibers closely packed in a parallel structure having a capillary effect and an abrasive effect. The fabric has a surface weight of less than 180 g/m2 and is loaded with medical, pharmaceutical or cosmetic active agents. The skin care fabric includes a warp-knitted fabric having a first surface and a second surface opposite the first surface, which is mechanically roughened and cut to become fluffy and yet short-haired and compact and resulting in a further surface enlargement of the fabric structure and a water absorbency of at least four times the surface weight of the fabric.

Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.